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In conclusion, we should offer the same profes-
sional management and quality of care to the many
patients with medically unexplained symptoms as we
offer to patients with explicable symptoms. Today this
is not the case, and we need to bring existing evidence
into medical education and to renew our management
of patients with medically unexplained symptoms in
general practice. In this process we must also be ready
to adjust paradigms about good communication
based on new evidence. This process should be driven
by comprehensive research into patients with
medically unexplained symptoms and by health serv-
ices research exploring the best possible implementa-
tion of appropriate management strategies.
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Direct to consumer advertising
Is at the crossroads of competing pressures from industry and health needs
The challenge for governments evaluatingdirect advertising of prescription only drugs tothe consumer is how to achieve maximum
benefits for health and wealth while minimising harm.
New Zealand’s health minister, Annette King, has
taken the advice of New Zealand’s health professional
and consumer groups and has decided that the poten-
tial benefits of “direct to consumer advertising” do not
justify the harms and so plans to ban it from 2005.w1
That will leave the United States as the only industrial-
ised country allowing full direct to consumer advertis-
ing of prescription medicines. An Australian review of
drug legislation in 2001 concluded that prohibiting
such advertising produces a net benefit for the
community as a whole.1 In 2002, the European Parlia-
ment rejected a proposal to allow advertising for
drugs used to treat asthma, AIDS, and diabetes directly
to the consumer. A 2004 Canadian parliamentary
inquiry recommended against direct to consumer
advertising because “Drug advertisements could
endanger rather than empower consumers by
minimizing risk information and exaggerating ben-
efits” and “could contribute to increased or inappro-
priate drug consumption.”2
Direct to consumer advertising increases the use of
drugs and medical services and increases wealth for
pharmaceutical, advertising, and media companies.3 It
increases prescribers’ workloads and increases
expenditure by patients, taxpayers, insurers, and large
employers. For example, General Motors USA has
identified direct to consumer advertising as a major
cost driver increasing payments for health care for its
workers and thus increasing the cost of building cars.w2
Such increased costs might be worth while if direct to
consumer advertising delivered value for money by
improving health.
Unfortunately, the situations where direct to
consumer advertising could be most beneficial (by
stimulating appropriate use of drugs for high priority
health needs) do not often match the situations where
it is most profitable. As one advertising industry execu-
tive explains: “Direct to consumer is suited for things
where patients have a greater interest than doctors.
Non-life threatening conditions, such as erectile
dysfunction . . .”w3 Such promotion may be beneficial as
well as harmful. For example, while the promotion of
sildenafil and its competitors may motivate men, who
might not do so otherwise, to see a general
practitioner, and possibly address other health needs, it
has been shown to increase distress if it raises expecta-
tions that are unfulfilledw4 and is a haphazard approach
to health promotion for populations. Direct to
consumer advertising is most profitable for expensive
new drugs.4 Because the long term health effects of
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new drugs are unknown it is often difficult to know
whether the increased costs are justified. There are also
opportunity costs when advertising stimulates rapid
adoption of new drugs without established advantages
over cheaper alternatives, especially in public health
systems with finite resources.
Proponents of direct to consumer advertising claim
it increases public knowledge. This might be so if it
delivered reliable balanced information. Such advertis-
ing does increase awareness of drugs, but its purpose,
as with all advertising, is to persuade rather than to
inform. Direct to consumer advertising leaves many
people with exaggerated perceptions of the benefits of
drugs.5 Providing balanced information about harms,
alternatives, and costs is likely to reduce efficacy and
profitability of advertisement. Demand stimulated by
such advertising creates dilemmas for doctors who
aspire to be both patient centred and evidence based.
For this reason, many health professionals and their
representative organisations strongly oppose advertis-
ing directly to consumers.6
In countries where full direct to consumer advertis-
ing is illegal, drug companies are increasingly pushing
the limits of regulatory systems, with disease oriented
advertising, public relations campaigns, reminders, and
unbranded direct to consumer advertising.w3 Require-
ments to provide any balancing information do not
exist because such advertising has arisen by default via
regulatory loopholes. For example, in Canada a price
advertising clause from 1978 has been used to allow
reminder advertisements, including advertising in July
2004 for a contraceptive patch by name without warn-
ings about adverse effects.7 w5 Earlier this year Glaxo-
SmithKline paid a celebrity, Impotence Australia, and a
couple who had used vardenafil to promote the drug
via the Australian news media.8 The brand name was
mentioned without appropriate balancing informa-
tion. In 2003 staff of the World Health Organization
expressed concern that disease oriented advertise-
ments in France that were funded by Pfizer,
manufacturer of atorvastatin, “contained misleading
statements and omissions likely to lead to unjustified
medicine use.”9 They recommended that governments
“urgently increase vigilance with respect to drug
promotion.” Few if any governments seem to be heed-
ing this advice. In 2004, Canada’s health minister,
Pierre Pettigrew, indicated that a nearly identical adver-
tisement was not subject to regulation because it fell
outside the legal definition of product specific
advertising.w6
Two studies of unbranded advertising directly to
consumers have been published. Prescribing of
sumatriptan was higher in cities in the United States
that had been exposed to a campaign in 1993 recom-
mending that people ask their doctor about a
“surprisingly effective” new treatment for migraine.10
Novartis’s unbranded television advertisements in the
Netherlands increased consultations for onychomyco-
sis and prescribing of terbinafine while decreasing use
of its competitor.11 The country’s health inspectorate
tried to stop this campaign, but a court allowed it
because neither the product nor the company was
named.
Governments are under pressure to create business
friendly environments for politically powerful indus-
tries to invest.12 At the same time they must manage
health services to give priority to health needs. Policy
on direct to consumer advertising is at the crossroads
of those competing pressures. In the face of unsuccess-
ful attempts at legislative change to allow advertising
directly to the consumer, lax enforcement of existing
laws may ease pressure on governments from those
politically powerful industries, but it is contrary to
democratic principles and may harm both public
health and national wealth.
The public is ill served when governments allow
promotion of prescription drugs that stretches the lim-
its of the law—and beyond. No country has been
successful at regulating any type of direct to consumer
advertising to ensure the public obtains reliable
balanced information on drug benefits and risks.3 6
Repeated breaches by companies speak for them-
selves.3 The potential awareness raising benefits of
direct to consumer advertising could be better targeted
and sustained at lower cost with less harm through
publicly funded and accountable drug information
services and health campaigns.
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